MBX Stock Forecast & Price Target

MBX Biosciences is supported by a differentiated precision peptide platform that aims to deliver smoother exposure, longer duration, and less frequent dosing, which could translate into better adherence and patient outcomes in endocrine and metabolic disease. The company’s lead assets have meaningful commercial potential: canvuparatide is viewed as a first once-weekly PTH replacement for an estimated ~$8B hypoparathyroidism market, while MBX 4291 showed encouraging blinded Phase 1 data with ~7% weight loss at 8 weeks, a 13–14 day Tmax, and only 12.5% nausea/vomiting/diarrhea in the MAD cohort through week 8. Financially, the bullish case is reinforced by modelled cash runway into 2029, approximately $440M in pro forma cash, and adjusted global peak revenues of about ~$2.2B across the pipeline, with MBX 4291 alone modelled at risk-adjusted $2.6B in 2040E.

MBX Biosciences is a clinical-stage biopharmaceutical company with no approved products, so its value depends heavily on early pipeline execution rather than recurring commercial revenue. Its main downside risks center on Phase 3 chronic hypoparathyroidism and Phase 1b obesity data falling short on efficacy or safety, alongside delays in recruitment, regulatory development, or commercial progress. The outlook is further weakened by cash need and dilution risk, plus intensifying regulatory and competitive pressure, including the possibility that weekly PTH competitors or launches outperform expectations.